Ionis Pharmaceuticals, Inc. Common Stock
IONS Real Time Price USDRecent trades of IONS by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by IONS's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$90,000 Jul 16, 2025 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
-
$90,000 Apr 16, 2025 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
-
$80,000 Jan 16, 2025 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
-
$80,000 Oct 15, 2024 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Health Issues
Estimated quarterly lobbying spending
IONS Revenue by Segment or Geography
New patents grants
-
Patent Title: Compounds and methods for reducing lrrk2 expression Mar. 04, 2025
-
Patent Title: Modified compounds and uses thereof Feb. 25, 2025
-
Patent Title: Compounds and methods for modulating scn2a Feb. 18, 2025
-
Patent Title: Modulators of diacyglycerol acyltransferase 2 (dgat2) Feb. 04, 2025
-
Patent Title: Methods for reducing ataxin-2 expression Jan. 07, 2025
-
Patent Title: Compounds and methods for modulating atxn1 Dec. 31, 2024
-
Patent Title: Modulators of malat1 expression Dec. 03, 2024
-
Patent Title: Selective antisense compounds and uses thereof Nov. 26, 2024
-
Patent Title: Compounds and methods for reducing mecp2 expression Nov. 26, 2024
-
Patent Title: Compounds and methods for modulating ube3a-ats Oct. 29, 2024
-
Patent Title: Selective reduction of allelic variants Oct. 08, 2024
-
Patent Title: Modulation of alpha synuclein expression Jul. 23, 2024
-
Patent Title: Modulators of irf4 expression Jul. 23, 2024
-
Patent Title: Compounds and methods for the modulation of proteins Jul. 09, 2024
-
Patent Title: Compounds and methods for modulating factor xii Jun. 25, 2024
-
Patent Title: Compounds and methods for modulation of dystrophia myotonica-protein kinase (dmpk) expression May. 14, 2024
-
Patent Title: Methods and compositions for inhibiting pmp22 expression Apr. 16, 2024
-
Patent Title: Modulators of complement factor b Mar. 12, 2024
-
Patent Title: Compounds and methods for reducing atxn2 expression Mar. 12, 2024
-
Patent Title: Compounds and methods for reducing lrrk2 expression Jan. 16, 2024
-
Patent Title: Antisense oligonucleotide compositions Jan. 02, 2024
-
Patent Title: Compositions and methods for modulating apolipoprotein (a) expression Dec. 26, 2023
-
Patent Title: Modulation of prekallikrein (pkk) expression Dec. 12, 2023
-
Patent Title: Compositions for modulating ataxin 2 expression Dec. 05, 2023
-
Patent Title: Oligomeric compounds for reducing dmpk expression Dec. 05, 2023
-
Patent Title: Compounds and methods for increasing stmn2 expression Dec. 05, 2023
-
Patent Title: Compounds and methods for modulating gfap Oct. 17, 2023
-
Patent Title: Modulators of pnpla3 expression Oct. 10, 2023
-
Patent Title: Compositions and their uses directed to huntingtin Sep. 19, 2023
-
Patent Title: Compounds and methods for reducing ifnar1 expression Sep. 12, 2023
-
Patent Title: Compositions and methods for modulating complement factor b expression Aug. 22, 2023
-
Patent Title: Compounds and methods for modulating plp1 Aug. 22, 2023
-
Patent Title: Selective antisense compounds and uses thereof Aug. 22, 2023
-
Patent Title: Compounds and methods for the modulation of amyloid-β precursor protein Aug. 22, 2023
-
Patent Title: Conjugated antisense compounds and their use Aug. 15, 2023
-
Patent Title: Modulation of gys1 expression Aug. 01, 2023
-
Patent Title: Methods for modulating fmr1 expression May. 30, 2023
-
Patent Title: Methods and compositions for modulating apolipoprotein (a) expression Apr. 25, 2023
-
Patent Title: Modulators of pcsk9 expression Apr. 25, 2023
-
Patent Title: Linkage modified oligomeric compounds and uses thereof Apr. 18, 2023
-
Patent Title: Compositions and methods for modulating pkk expression Mar. 28, 2023
-
Patent Title: Compounds and methods for reducing atxn3 expression Feb. 21, 2023
-
Patent Title: Oligomeric compounds comprising bicyclic nucleotides and uses thereof Jan. 31, 2023
-
Patent Title: Modulators of foxp3 expression Jan. 10, 2023
-
Patent Title: Compounds and methods for modulating atxn1 Jan. 03, 2023
-
Patent Title: Modulation of transthyretin expression Dec. 27, 2022
-
Patent Title: Methods for reducing lrrk2 expression Dec. 20, 2022
-
Patent Title: Methods for treating hypercholesterolemia Dec. 20, 2022
-
Patent Title: Modulators of apol1 expression Dec. 13, 2022
-
Patent Title: Compositions and methods for modulation of protein aggregation Nov. 08, 2022
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to IONS
Recent picks made for IONS stock on CNBC
ETFs with the largest estimated holdings in IONS
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $IONS stock a Buy, Sell, or Hold?
- What is the price target for $IONS stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $IONS stock?
- Who owns the most shares of $IONS stock?
- What funds own $IONS stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view IONS Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.